title: [Are treatments with statins that are considered unsuitable really unsuitable?].
abstract: In the Catalonian Institute of health there are 2 well-established circumstances for indicating lipid-lowering drug treatment with statins in the primary prevention of ischaemic heart disease. These are, severe hypercholesterolaemia, with a low density lipoprotein cholesterol equal to or greater than 240mg/dL, or above 130mg/dL when the coronary risk is equal to or greater than 10% at 10 years. There are data that suggest that these 2 criteria are not the only ones used in routine clinical practice, as such that the majority of patients to whom it is indicated, do not meet either of these 2 conditions. This study aims to determine the characteristics of the patients when statins are indicated outside the aforementioned circumstances. It is concluded that around 40% of patients have clinical characteristics that could justify the treatment. The level of suitability could not be established in about 33% of the patients, due to not being able to determine the coronary risk.
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Cinta
authors.initials: C
authors.lastname: Estrada Alifonso
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España. Electronic address: 16730jvc@comb.cat.
authors.forename: Jordi
authors.initials: J
authors.lastname: Vilaseca Canals
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: M Ángeles
authors.initials: MÁ
authors.lastname: Méndez Trías
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Silvia
authors.initials: S
authors.lastname: Lozano Ovalle
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Javier
authors.initials: J
authors.lastname: Jusmet Miquel
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Victoria
authors.initials: V
authors.lastname: Torres Machado
authors.affiliation: CAP Just Oliveras, ABS Sant Josep, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Esteban
authors.initials: E
authors.lastname: Castro Rivera
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000008:administration & dosage / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D017202:Myocardial Ischemia / Q000517:prevention & control*; D011322:Primary Prevention; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Estatinas; HMG-CoA; Hipercolesterolemia; Hydroxymethylglutaryl-CoA reductase inhibitors; Hypercholesterolemia; Inhibidores de la Hidroximetilglutaril-CoA reductasa; Riesgo; Risk; Statins